Moyamoya disease: epidemiology, clinical features, pathogenesis, diagnosis and therapeutic interventions

Xinyue Cheng1, Ying Cao1, Junbo Duan1

  • 1Center for Stem Cell and Translational Medicine, School of Life Science, Anhui University, Hefei, 230601, China.

Molecular Biomedicine
|October 9, 2025
PubMed

Insights

Moyamoya disease (MMD) is a rare cerebrovascular disorder. Research is advancing understanding of its genetic basis and molecular mechanisms using stem cell models to develop new therapies.

Area of Science:

  • Neuroscience
  • Genetics
  • Vascular Biology

Background:

  • Moyamoya disease (MMD) is a rare cerebrovascular disorder causing progressive stenosis of intracranial arteries.
  • Pathogenesis involves genetic factors, immune responses, and environmental triggers, with the RNF213 p.R4810K variant being a key susceptibility factor.
  • Limited patient tissues and inadequate animal models hinder understanding and therapeutic development.

Purpose of the Study:

  • To provide a systematic overview of MMD epidemiology, clinical features, and genetics.
  • To highlight recent progress in deciphering the molecular basis of MMD.
  • To discuss the potential of iPSC technology and CRISPR gene editing for MMD research and therapy.

Main Methods:

  • Review of existing literature on MMD epidemiology, genetics, and molecular mechanisms.
  • Discussion of diagnostic tools like digital subtraction angiography (DSA).
  • Exploration of advanced research models including patient-derived vascular organoids and induced pluripotent stem cells (iPSCs).

Main Results:

  • The RNF213 p.R4810K variant is a significant genetic factor, particularly in East Asian populations.
  • Patient-derived models and iPSC technology offer new avenues for drug screening and biomarker identification.
  • Surgical revascularization improves cerebral perfusion but does not alter the underlying disease process.

Conclusions:

  • Innovative approaches like iPSC technology combined with CRISPR gene editing are crucial for modeling MMD vasculopathy and investigating RNF213 mutations.
  • These advanced techniques provide novel insights into MMD pathogenesis.
  • Precision repair strategies and targeted therapies hold promise for future MMD treatment.

Related Concept Videos

Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
325
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
465
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
367
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
354
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.9K
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
293